Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2179407
Max Phase: Preclinical
Molecular Formula: C27H37N5O2
Molecular Weight: 463.63
Molecule Type: Small molecule
Associated Items:
ID: ALA2179407
Max Phase: Preclinical
Molecular Formula: C27H37N5O2
Molecular Weight: 463.63
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C([C@@H]1C[C@H](n2cc(C3CCCCC3)nn2)CN1C(=O)CCCc1ccccc1)N1CCCC1
Standard InChI: InChI=1S/C27H37N5O2/c33-26(15-9-12-21-10-3-1-4-11-21)31-19-23(18-25(31)27(34)30-16-7-8-17-30)32-20-24(28-29-32)22-13-5-2-6-14-22/h1,3-4,10-11,20,22-23,25H,2,5-9,12-19H2/t23-,25-/m0/s1
Standard InChI Key: RBLIZQQDPZHRGB-ZCYQVOJMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 463.63 | Molecular Weight (Monoisotopic): 463.2947 | AlogP: 4.11 | #Rotatable Bonds: 7 |
Polar Surface Area: 71.33 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 0.49 | CX LogP: 3.92 | CX LogD: 3.92 |
Aromatic Rings: 2 | Heavy Atoms: 34 | QED Weighted: 0.62 | Np Likeness Score: -1.14 |
1. Van der Veken P, Fülöp V, Rea D, Gerard M, Van Elzen R, Joossens J, Cheng JD, Baekelandt V, De Meester I, Lambeir AM, Augustyns K.. (2012) P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy., 55 (22): [PMID:23121075] [10.1021/jm301060g] |
Source(1):